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Purpose or Objective: The majority of intraprostatic 
recurrences after radical prostate radiotherapy occur at the 
site of initial tumour, in previous reported series. However, 
there is no published data directly comparing recurrence 
patterns after different modalities of radiotherapy. The aim 
of this study was to investigate differences in spatial pattern 
of intra-prostatic recurrences on multiparametric MRI, after 
external beam radiotherapy or brachytherapy. 
 
Material and Methods: We identified 382 consecutive 
patients referred for multiparametric MRI after previous 
prostate cancer treatment. Patients with post-radiotherapy 
biochemical recurrence and intraprostatic recurrence on MRI 
were included in the study. Scans were independently 
reviewed by two radiologists. The location of recurrence was 
mapped to prostate sectors based on European consensus 
guidelines. The chi-square test was used to analyse 
differences in site of recurrence between modalities of 
radiotherapy. 
 
Results: 66 patients who had radical radiotherapy between 
1997 and 2013 had intraprostatic recurrence on MRI. The 
D’Amico risk stratification at initial diagnosis was 14% low-
risk, 34% intermediate-risk and 52% high-risk. The series 
consisted of 34 patients after external beam radiotherapy 
(EBRT), 20 patients after low-dose rate brachytherapy (LDR) 
and 12 after high-dose rate brachytherapy monotherapy (HDR 
mono). 68% of the EBRT recurrences had received a dose-
fractionation schedule with an EQD2 less than 74 Gy. The 
mean time between the end of radiotherapy and imaging 
recurrence was 77 months (95% CI 68 – 85 months) with no 
significant differences between treatment groups. 80% of 
patients did not have any associated pelvic bony metastasis 
or nodal disease. 88% of patients had a contiguous 
intraprostatic recurrence. The median recurrence size 
detected on MRI was 2.0 cm (range 0.6 – 4.2 cm). 
Recurrences after EBRT were more likely to involve multiple 
sectors of the prostate. 71% of EBRT recurrences involved the 
apex compared to 30% after LDR and 25% after HDR mono (p 
= 0.003). In the LDR group, recurrences involved the base of 
the gland in 60% of cases, compared to 41% after EBRT and 
8% after HDR mono (p = 0.016). 21% of patients underwent 
salvage treatment with cryotherapy, HDR brachytherapy or 
prostatectomy. 
 
Conclusion: Apical recurrences predominated in patients 
following EBRT. This highlights the need for MR-fusion during 
EBRT target definition because the apex is difficult to 
visualise on CT. Basal recurrences were associated with LDR 
brachytherapy, which may reflect a tendency of radioactive 
seed migration away from the base. The use of 
multiparametric MRI facilitates identification of patients for 
focal salvage treatment. 
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Purpose or Objective: The average 5-year survival rate of 
men diagnosed with prostate cancer (PCa) is 93%. The long 
life expectancy exposes them to a greater risk of developing 
second primary cancers. To quantify the risk of radiation 
induced second primary cancer, we analysed data of PCa 
patients based on our Cancer Registry.  
 
Material and Methods: We analysed 19.538 patients treated 
for PCa from 1988 until 2008. They were either treated with 
surgery (RPE only) or received radiation therapy as primary 
(RT only) or as postoperative treatment (RT after RPE). 
Statistical analysis was performed using a stratified Cox 
proportional hazard model and a chi-square test. 
 
Results: Patients who received RT only were 5 years older 
(median) than patients who underwent RPE only or RT after 
RPE. Second primary cancers were observed with 13.1% and 
13.6% in the RPE only and in the RT after RPE group and 
16.4% in the RT only group (p= 0.0001), respectively. Colon 
carcinoma was seen in the RPE only and RT only group in 
roughly 10 percent, whereas in the RT after RPE group in 
14.6% (p= 0.2140). Bronchial cancer surpassed 10% in the RT 
only group (12.5%) vs. 9.7% and 7.8% in the RPE only and the 
RT after RPE group (p= 0.0552). Bladder cancer was observed 
with roughly 10% in the RPE only (10.2%) and RT after RPE 
(10.4%) group versus 15.5% in the RT only group (p= 0.0007). 
Rectal cancer after treatment of PCa was diagnosed in 5.7%, 
7% and 3.1% in the RPE only, RT only and RT after RPE group 
(p= 0.1037). Within the first 10 – 15 years the cumulative 
hazard curves for second primary cancers gave no hint to an 
increased tumor risk due to prior treatment. After 15 years 
there are hardly any cases left and the occurring events can 
no longer be reasonably interpreted. Cox proportional hazard 
ratio revealed that patients with a higher age have a 
significantly higher risk of developing second primary cancer 
(Hazard Ratio 1.279 in 60 - <65 year old patients vs. 2.169 in 
≥75 year old patients, p <0.0001).  
 
Conclusion: Based on this population with PCa from the PSA 
era the incidences of second primary cancers did not differ 
significantly between the three arms apart from bladder and 
lung cancer that came close to being significantly different. 
However, these differences cannot reliably be ascribed to 
radiation, but to other factors such as older age, lifestyle 
habits like smoking and the well known fact that cancer 
survivors generally have an increased risk of new tumor 
formation.  
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